STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGLS
  4. [EFFECT] Regulus Therapeutics Inc. SEC Filing

[EFFECT] Regulus Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 1, 2025
Accession Number: 0001104659-25-062440
Submission Type: POS AM
CIK: 0001505512
Company Name: Regulus Therapeutics Inc.
File Number: 333-271847

Source: View Original Filing on SEC EDGAR

Stock RGLS logo
Regulus Therapeu

NASDAQ:RGLS

RGLS Rankings

#3177 Ranked by Market Cap
N/A Ranked by Dividends

RGLS Latest News

May 8, 2025
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
Apr 30, 2025
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Apr 2, 2025
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Mar 27, 2025
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mar 13, 2025
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

RGLS Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Regulus Therapeutics Inc. SEC Filing
Aug 14, 2025
[SCHEDULE 13G/A] Regulus Therapeutics Inc. SEC Filing
Jul 7, 2025
[15-12G] Regulus Therapeutics Inc. SEC Filing
Jul 2, 2025
[EFFECT] Regulus Therapeutics Inc. SEC Filing
Jul 2, 2025
[EFFECT] Regulus Therapeutics Inc. SEC Filing

RGLS Stock Data

545.56M
67.29M
2.71%
82.87%
2.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO